Overview

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Status:
Recruiting

Trial end date:
2022-05-18

Target enrollment:
0

Participant gender:
All

Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization. Subjects will be randomized to receive either standard-of-care products or the study medication plus supportive care, while being hospitalized for COVID-19. Participants will be randomized to one of the following groups: 1. Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus optimized supportive care, OR 2. Interferon-beta-1a, 22 or 44 micrograms subcutaneously on days 1, 3 and 6, plus optimized supportive care OR 3. Optimized support care, all or until discharge from hospital, whichever occurs first

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborators:

AbbVie
Apotex Inc.

Treatments:

Interferon beta-1a
Interferon-beta
Interferons
Lopinavir
Remdesivir
Ritonavir

Criteria

Inclusion Criteria:

1. ≥ 18 years of age

2. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
commercial or public health assay in any specimen prior to randomization.

3. Hospitalized at a participating centre

Exclusion Criteria:

1. Anticipated transfer to another hospital, within 72 hours, which is not a study site

2. Expected to not survive beyond 24 hours

3. Known allergy to study medication or its components (non-medicinal ingredients)

4. Receiving one of the study drugs at time of enrolment